Drug-drug interactions and adverse drug reactions: The bollards and flashing lights syndrome

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 2, 2005, Pages 97-99

  Li Wan Po, A ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CODEINE; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; MORPHINE;

ADVERSE DRUG REACTION; DRUG CLEARANCE; DRUG INFORMATION; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; HUMAN; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; RHABDOMYOLYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ATTITUDE TO HEALTH; DRUG INTERACTIONS; HUMANS; INFORMATION DISSEMINATION;

EID: 27744537332     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00635.x     Document Type: Editorial

References (17)

1. Magnus D, Rodgers S, Avery AJ (2002) GPs' views on computerized drug interactions alert: questionnaire survey. Journal of Clinical Pharmacy and Therapeutics, 27, 377-382.
2. Ashworth M (2002) Re: GPs' views on computerised drug interactions alert. Journal of Clinical Pharmacy and Therapeutics, 27, 311-312.
3. Tirkkonen T, Laine K (2004) Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital. Clinical Pharmacology and Therapeutics, 76, 639-647.
4. Martin AM, Nolan D, Gaudieri S et al. (2004) Pre-disposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Science, 101, 4180-4185.
5. Ulrich CM, Yasui Y, Storb R et al. (2001) Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylene-tetrahydrofolate reductase C677T polymorphism. Blood, 98, 231-234.
6. Pirmohamed M, James S, Meakin S et al. (2004) Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18820 patients. BMJ, 329, 15-19.
7. Aronson JK (2004) Drug interactions - information, education, and the British National Formulary. British Journal of Clinical Pharmacology, 57, 371-372.
8. Gasche Y DY, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. New England Journal of Medicine, 351, 2827-2831.
9. Ozaki H, Ishikawa T, Ishii T, Toyoda A, Murano T, Miyashita Y, Shirai K (2005) Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. Journal of Clinical Pharmacy and therapeutics, 30, 189-192.
10. Johnson DE, Wolfgang GHI (2000) Predicting human safety: screening and computational approaches. Drug Discovery Today, 5, 445-454.
11. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients - a meta-analysis of prospective studies. JAMA, 279, 1200-1205.
12. Wiffen P, Gill M, Edwards J, Moore A (2002) Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies. Bandolier Extra, June, 1-16.
13. Johnson JA, Bootman JL (1995) Drug-related morbidity and mortality. A cost-of-illness model. Archives of Internal Medicine, 155, 1949-1956.
14. Ernst FR, Grizzle AJ (2001) Drug-related morbidity and mortality: updating the cost-of-illness model. Journal of the American Pharmaceutical Association, 41, 192-199.
15. Li Wan Po A, Herxheimer A, Poolsup N, Aziz Z. How do Cochrane reviewers address adverse effects of drug therapy? http://www.cochrane.org/colloquia/ abstracts/capetown/capetowno39.html (accessed 19 February 2005).
16. Nightingale PG, Adu D, Richards NT, Peters M (2000) Implementation of rules based computerised bedside prescribing and administration: intervention study. BMJ, 320, 750-753.
17. Anton C, Nightingale PG, Adu D, Lipkin G, Ferner RE (2004) Improving prescribing using a rule based prescribing system. Quality and Safety in Health Care, 13, 186-190.